In summary, genome-wide technologies have greatly refined the molecular diagnosis of B-ALL, at the same time leading to the discovery of diverse PAX5 alterations as primary or secondary events in B cell transformation. The gene discussed is PAX5; the disease is acute lymphoblastic leukemia.